Improving thrombolysis with encapsulated plasminogen activators and clinical relevance to myocardial infarction and stroke

Jonathan K Leach, Eugene Patterson, Edgar A. O'Rear

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Our efforts have focused on investigating the potential benefit of encapsulated thrombolytic agents for treatment of clot-based crises. Liposome encapsulated plasminogen activators (LEPAs) have demonstrated improved thrombolysis in vivo in multiple laboratories. Compared to free agents, LEPAs demonstrate faster reperfusion times, reduced residual clot masses, and more rapid and complete restoration of blood flow. We have encapsulated streptokinase in both liposomes (LESK) and polymer microcapsules (MESK). Both formulations demonstrated reductions in reperfusion times, residual clot mass, and improved return of flow compared to identical dosages of free streptokinase in a thrombosed rabbit carotid, with MESK resulting in comparable or even greater improvements. In addition, marked reductions in bleeding complications and ventricular infarct size have been observed in a canine model of acute myocardial infarction. The mechanism for MESK has recently been explored in our laboratory using multiple microscopic techniques. MESK appears to resist adsorption to the leading edge of the thrombus, a common limitation for the permeation of free plasminogen activators. By avoiding adsorption and penetrating the thrombus, greater spatial distribution of the agent within the clot can be achieved. This data suggests that encapsulation of streptokinase could provide a therapeutic option for treatment of thrombosed arteries.

Original languageEnglish (US)
Pages (from-to)225-228
Number of pages4
JournalClinical Hemorheology and Microcirculation
Volume30
Issue number3-4
StatePublished - 2004
Externally publishedYes

Fingerprint

Plasminogen Activators
Streptokinase
Stroke
Myocardial Infarction
Liposomes
Thrombosis
Adsorption
Reperfusion
Carotid Artery Thrombosis
Fibrinolytic Agents
Capsules
Canidae
Polymers
Therapeutics
Arteries
Hemorrhage
Rabbits
MESK

ASJC Scopus subject areas

  • Hematology
  • Physiology

Cite this

Improving thrombolysis with encapsulated plasminogen activators and clinical relevance to myocardial infarction and stroke. / Leach, Jonathan K; Patterson, Eugene; O'Rear, Edgar A.

In: Clinical Hemorheology and Microcirculation, Vol. 30, No. 3-4, 2004, p. 225-228.

Research output: Contribution to journalArticle

@article{543c1c891dae4b68b6ee1d642a4a928d,
title = "Improving thrombolysis with encapsulated plasminogen activators and clinical relevance to myocardial infarction and stroke",
abstract = "Our efforts have focused on investigating the potential benefit of encapsulated thrombolytic agents for treatment of clot-based crises. Liposome encapsulated plasminogen activators (LEPAs) have demonstrated improved thrombolysis in vivo in multiple laboratories. Compared to free agents, LEPAs demonstrate faster reperfusion times, reduced residual clot masses, and more rapid and complete restoration of blood flow. We have encapsulated streptokinase in both liposomes (LESK) and polymer microcapsules (MESK). Both formulations demonstrated reductions in reperfusion times, residual clot mass, and improved return of flow compared to identical dosages of free streptokinase in a thrombosed rabbit carotid, with MESK resulting in comparable or even greater improvements. In addition, marked reductions in bleeding complications and ventricular infarct size have been observed in a canine model of acute myocardial infarction. The mechanism for MESK has recently been explored in our laboratory using multiple microscopic techniques. MESK appears to resist adsorption to the leading edge of the thrombus, a common limitation for the permeation of free plasminogen activators. By avoiding adsorption and penetrating the thrombus, greater spatial distribution of the agent within the clot can be achieved. This data suggests that encapsulation of streptokinase could provide a therapeutic option for treatment of thrombosed arteries.",
author = "Leach, {Jonathan K} and Eugene Patterson and O'Rear, {Edgar A.}",
year = "2004",
language = "English (US)",
volume = "30",
pages = "225--228",
journal = "Clinical Hemorheology and Microcirculation",
issn = "1386-0291",
publisher = "IOS Press",
number = "3-4",

}

TY - JOUR

T1 - Improving thrombolysis with encapsulated plasminogen activators and clinical relevance to myocardial infarction and stroke

AU - Leach, Jonathan K

AU - Patterson, Eugene

AU - O'Rear, Edgar A.

PY - 2004

Y1 - 2004

N2 - Our efforts have focused on investigating the potential benefit of encapsulated thrombolytic agents for treatment of clot-based crises. Liposome encapsulated plasminogen activators (LEPAs) have demonstrated improved thrombolysis in vivo in multiple laboratories. Compared to free agents, LEPAs demonstrate faster reperfusion times, reduced residual clot masses, and more rapid and complete restoration of blood flow. We have encapsulated streptokinase in both liposomes (LESK) and polymer microcapsules (MESK). Both formulations demonstrated reductions in reperfusion times, residual clot mass, and improved return of flow compared to identical dosages of free streptokinase in a thrombosed rabbit carotid, with MESK resulting in comparable or even greater improvements. In addition, marked reductions in bleeding complications and ventricular infarct size have been observed in a canine model of acute myocardial infarction. The mechanism for MESK has recently been explored in our laboratory using multiple microscopic techniques. MESK appears to resist adsorption to the leading edge of the thrombus, a common limitation for the permeation of free plasminogen activators. By avoiding adsorption and penetrating the thrombus, greater spatial distribution of the agent within the clot can be achieved. This data suggests that encapsulation of streptokinase could provide a therapeutic option for treatment of thrombosed arteries.

AB - Our efforts have focused on investigating the potential benefit of encapsulated thrombolytic agents for treatment of clot-based crises. Liposome encapsulated plasminogen activators (LEPAs) have demonstrated improved thrombolysis in vivo in multiple laboratories. Compared to free agents, LEPAs demonstrate faster reperfusion times, reduced residual clot masses, and more rapid and complete restoration of blood flow. We have encapsulated streptokinase in both liposomes (LESK) and polymer microcapsules (MESK). Both formulations demonstrated reductions in reperfusion times, residual clot mass, and improved return of flow compared to identical dosages of free streptokinase in a thrombosed rabbit carotid, with MESK resulting in comparable or even greater improvements. In addition, marked reductions in bleeding complications and ventricular infarct size have been observed in a canine model of acute myocardial infarction. The mechanism for MESK has recently been explored in our laboratory using multiple microscopic techniques. MESK appears to resist adsorption to the leading edge of the thrombus, a common limitation for the permeation of free plasminogen activators. By avoiding adsorption and penetrating the thrombus, greater spatial distribution of the agent within the clot can be achieved. This data suggests that encapsulation of streptokinase could provide a therapeutic option for treatment of thrombosed arteries.

UR - http://www.scopus.com/inward/record.url?scp=3242658885&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3242658885&partnerID=8YFLogxK

M3 - Article

VL - 30

SP - 225

EP - 228

JO - Clinical Hemorheology and Microcirculation

JF - Clinical Hemorheology and Microcirculation

SN - 1386-0291

IS - 3-4

ER -